JP2023554405A5 - - Google Patents

Info

Publication number
JP2023554405A5
JP2023554405A5 JP2023536454A JP2023536454A JP2023554405A5 JP 2023554405 A5 JP2023554405 A5 JP 2023554405A5 JP 2023536454 A JP2023536454 A JP 2023536454A JP 2023536454 A JP2023536454 A JP 2023536454A JP 2023554405 A5 JP2023554405 A5 JP 2023554405A5
Authority
JP
Japan
Prior art keywords
alkyl
alkoxy
group
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023536454A
Other languages
English (en)
Japanese (ja)
Other versions
JP7622229B2 (ja
JP2023554405A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2021/061839 external-priority patent/WO2022130270A1/en
Publication of JP2023554405A publication Critical patent/JP2023554405A/ja
Publication of JP2023554405A5 publication Critical patent/JP2023554405A5/ja
Priority to JP2025005438A priority Critical patent/JP7744538B2/ja
Application granted granted Critical
Publication of JP7622229B2 publication Critical patent/JP7622229B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023536454A 2020-12-17 2021-12-16 N-(2-(4-シアノチアゾリジン-3-イル)-2-オキソエチル)-キノリン-4-カルボキサミド Active JP7622229B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025005438A JP7744538B2 (ja) 2020-12-17 2025-01-15 N-(2-(4-シアノチアゾリジン-3-イル)-2-オキソエチル)-キノリン-4-カルボキサミド

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063126593P 2020-12-17 2020-12-17
US63/126,593 2020-12-17
PCT/IB2021/061839 WO2022130270A1 (en) 2020-12-17 2021-12-16 N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)- quinoline-4-carboxamides

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025005438A Division JP7744538B2 (ja) 2020-12-17 2025-01-15 N-(2-(4-シアノチアゾリジン-3-イル)-2-オキソエチル)-キノリン-4-カルボキサミド

Publications (3)

Publication Number Publication Date
JP2023554405A JP2023554405A (ja) 2023-12-27
JP2023554405A5 true JP2023554405A5 (cg-RX-API-DMAC7.html) 2024-11-06
JP7622229B2 JP7622229B2 (ja) 2025-01-27

Family

ID=79164845

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023536454A Active JP7622229B2 (ja) 2020-12-17 2021-12-16 N-(2-(4-シアノチアゾリジン-3-イル)-2-オキソエチル)-キノリン-4-カルボキサミド
JP2025005438A Active JP7744538B2 (ja) 2020-12-17 2025-01-15 N-(2-(4-シアノチアゾリジン-3-イル)-2-オキソエチル)-キノリン-4-カルボキサミド

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025005438A Active JP7744538B2 (ja) 2020-12-17 2025-01-15 N-(2-(4-シアノチアゾリジン-3-イル)-2-オキソエチル)-キノリン-4-カルボキサミド

Country Status (20)

Country Link
US (2) US20240101549A1 (cg-RX-API-DMAC7.html)
EP (1) EP4263535A1 (cg-RX-API-DMAC7.html)
JP (2) JP7622229B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230122080A (cg-RX-API-DMAC7.html)
CN (1) CN116745291B (cg-RX-API-DMAC7.html)
AR (1) AR124379A1 (cg-RX-API-DMAC7.html)
AU (2) AU2021403827B2 (cg-RX-API-DMAC7.html)
CA (1) CA3204318A1 (cg-RX-API-DMAC7.html)
CL (1) CL2023001763A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023008921A2 (cg-RX-API-DMAC7.html)
CR (1) CR20230314A (cg-RX-API-DMAC7.html)
DO (1) DOP2023000124A (cg-RX-API-DMAC7.html)
EC (1) ECSP23053033A (cg-RX-API-DMAC7.html)
IL (1) IL303655A (cg-RX-API-DMAC7.html)
MX (1) MX2023007287A (cg-RX-API-DMAC7.html)
PE (1) PE20232046A1 (cg-RX-API-DMAC7.html)
SA (1) SA523441175B1 (cg-RX-API-DMAC7.html)
TW (1) TW202239407A (cg-RX-API-DMAC7.html)
UY (1) UY39569A (cg-RX-API-DMAC7.html)
WO (1) WO2022130270A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY39569A (es) * 2020-12-17 2022-07-29 Astrazeneca Ab N-(2-(4-cianotiazolidin-3-il)-2-oxoetil)- quinolin-4-carboxamidas
AU2023288645A1 (en) * 2022-06-21 2025-02-13 Astrazeneca Ab Solid-state forms of n-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)- 6-morpholinoquinoline-4-carboxamide
CN119562951A (zh) * 2022-06-21 2025-03-04 阿斯利康(瑞典)有限公司 N-(2-(4-氰基噻唑烷-3-基)-2-氧代乙基)-喹啉-4-甲酰胺
WO2026119802A1 (en) 2024-12-02 2026-06-11 Astrazeneca Ab Dosing regimen for the treatment of fap-mediated conditions

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW521072B (en) 1997-06-02 2003-02-21 Meiji Seika Kaisha 4-quinolinol derivatives and fungicides containing the same as an active ingredient used for agriculture and horticulture
FR2795726A1 (fr) 1999-06-30 2001-01-05 Aventis Cropscience Sa Nouveaux pyrazoles fongicides
GB9928330D0 (en) 1999-11-30 2000-01-26 Ferring Bv Novel antidiabetic agents
DE10006453A1 (de) 2000-02-14 2001-08-16 Bayer Ag Piperidylcarbonsäuren als Integrinantagonisten
GB0010183D0 (en) 2000-04-26 2000-06-14 Ferring Bv Inhibitors of dipeptidyl peptidase IV
GB0010188D0 (en) 2000-04-26 2000-06-14 Ferring Bv Inhibitors of dipeptidyl peptidase IV
AU2001277754B2 (en) 2000-08-10 2005-09-29 Mitsubishi Tanabe Pharma Corporation Proline derivatives and use thereof as drugs
JP2003026698A (ja) 2000-09-27 2003-01-29 Tokyo Inst Of Technol 新規化合物、固定化物及び蛋白質のスクリーニング方法
GB0125445D0 (en) 2001-10-23 2001-12-12 Ferring Bv Protease Inhibitors
AU2004207731B2 (en) 2003-01-31 2009-08-13 Sanwa Kagaku Kenkyusho Co., Ltd. Compound inhibiting dipeptidyl peptidase iv
EP2210607B1 (en) * 2003-09-26 2011-08-17 Exelixis Inc. N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer
WO2005087742A1 (en) 2004-03-08 2005-09-22 Exelixis, Inc. Metabolic kinase modulators and methods of use as pesticides
TWI366438B (en) 2004-08-12 2012-06-21 Ishihara Sangyo Kaisha Fungicidal composition containing acid amide derivative
WO2007017423A2 (en) 2005-08-11 2007-02-15 F. Hoffmann-La Roche Ag Pharmaceutical composition comprising a dpp-iv inhibitor
EP1760076A1 (en) 2005-09-02 2007-03-07 Ferring B.V. FAP Inhibitors
JP2010510246A (ja) 2006-11-21 2010-04-02 スミスクライン ビーチャム コーポレーション アミド抗ウイルス化合物
CN102884059B (zh) 2010-03-11 2015-08-26 大日本住友制药株式会社 N-酰基环胺衍生物或其可药用盐
EP4706663A3 (en) 2011-08-30 2026-05-20 Trustees Of Tufts College FAP-ACTIVATED PROTEASOME INHIBITORS USED TO TREAT SOLID TUMORS
UA110862C2 (uk) 2011-10-07 2016-02-25 Ф. Хоффманн-Ля Рош Аг Похідні етинілу як алостеричні модулятори метаботропного рецептора глутамату mglur 5
WO2013107820A1 (en) 2012-01-17 2013-07-25 Universiteit Antwerpen Novel fap inhibitors
EP2874632B1 (en) 2012-07-23 2020-06-17 Sphaera Pharma Pte. Ltd Triazine compound having pi3k-alpha and mtor inhibiting activity
MX2016012573A (es) 2014-03-28 2018-02-19 Sunshine Lake Pharma Co Ltd Compuestos de dihidropirimidina y su aplicacion en productos farmaceuticos.
JP2017513954A (ja) 2014-04-22 2017-06-01 ニンバス アイリス, インコーポレイテッド Irak阻害剤およびその使用
AU2015315174B2 (en) 2014-09-10 2019-12-12 Epizyme, Inc. Smyd inhibitors
WO2016061751A1 (en) * 2014-10-22 2016-04-28 Merck Sharp & Dohme Corp. Ethyl n-boc piperidinyl pyrazolo pyridones as janus kinase inhibitors
WO2017189569A1 (en) 2016-04-25 2017-11-02 Trustees Of Tufts College Multimediator dpp4 and fap inhibitors, and uses related thereto
CN118359610A (zh) 2016-09-16 2024-07-19 生命医药有限责任公司 Menin-mll相互作用的抑制剂
WO2018161033A1 (en) 2017-03-02 2018-09-07 Wright, Adrian Small molecule ire1-alpha inhibitors
CN108690043B (zh) 2017-04-11 2019-10-18 东莞东阳光科研发有限公司 喹啉类衍生物及其制备方法和用途
US11358940B2 (en) 2017-04-20 2022-06-14 The Regents Of The University Of California K-Ras modulators
US11584744B2 (en) 2017-06-23 2023-02-21 University Of Washington Inhibitors of type 1 methionyl-tRNA synthetase and methods of using them
JP7365332B2 (ja) 2017-08-07 2023-10-19 ジョイント・ストック・カンパニー “バイオキャド” Cdk8/19阻害薬としての新規ヘテロ環式化合物
EP3700527A4 (en) 2017-10-25 2021-03-10 Children's Medical Center Corporation PAPD5 INHIBITORS AND METHOD OF USING THEM
AU2018386298B2 (en) 2017-12-15 2023-09-07 Praxis Biotech LLC Inhibitors of fibroblast activation protein
JP2021506862A (ja) 2017-12-19 2021-02-22 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung Tlr7/8アンタゴニストおよびそれらの使用
PH12020551205A1 (en) 2018-02-06 2021-04-19 Univ Heidelberg Fap inhibitors
SG11202100818RA (en) 2018-07-31 2021-02-25 Merck Patent Gmbh Tlr7/8 antagonists and uses thereof
US12662494B2 (en) 2018-08-08 2026-06-23 Sumitomo Pharma Co., Ltd. Optically active bridged piperidine derivative
TWI815954B (zh) 2018-08-27 2023-09-21 日商住友製藥股份有限公司 光學活性氮雜雙環衍生物
US10815241B2 (en) 2018-08-27 2020-10-27 Sumitomo Dainippon Pharma Co., Ltd. Optically active azabicyclo ring derivative
CN113811529A (zh) * 2018-12-21 2021-12-17 普拉西斯生物技术有限责任公司 成纤维细胞激活蛋白抑制剂
US12559487B2 (en) 2019-09-27 2026-02-24 Sumitomo Pharma Co., Ltd. Crosslinked optically active secondary amine derivative
BR112022008041A2 (pt) 2019-11-06 2022-08-16 Yuhan Corp Compostos de pirrolidina e piperidina
UY39569A (es) * 2020-12-17 2022-07-29 Astrazeneca Ab N-(2-(4-cianotiazolidin-3-il)-2-oxoetil)- quinolin-4-carboxamidas

Similar Documents

Publication Publication Date Title
CN1104430C (zh) 抑制血管生成的哒嗪胺
JP6307091B2 (ja) β2アドレナリンアゴニスト活性およびM3ムスカリンアンタゴニスト活性を有する新規のシクロヘキシルおよびキヌクリジニルカルバメート誘導体
US6071927A (en) Spiro-piperidine derivatives and their use as therapeutic agents
CA3016068C (en) Antibacterial compounds and uses thereof
CN101868448B (zh) 5-[(3,3,3-三氟-2-羟基-1-芳基丙基)氨基]-1h-喹啉-2-酮、它们的制备方法和它们作为抗炎药的用途
US20150183757A1 (en) Method of producing beraprost
JP2022540432A5 (cg-RX-API-DMAC7.html)
HK1054386A1 (zh) 取代的2-硫代-3,5-二氰基-4-芳基-6-氨基吡啶及其應用
JP2006525298A (ja) アゼチジンカルボキサミド誘導体及びcb1レセプター媒介障害の治療におけるその使用
JP2003525268A (ja) アゼチジン誘導体、それらの製造及びそれらを含有する製薬学的組成物
CN1312803A (zh) 新颖的苯并吡喃或苯并噻喃衍生物
JP2019513745A5 (cg-RX-API-DMAC7.html)
JP2022540586A5 (cg-RX-API-DMAC7.html)
CA2368502A1 (en) C10 heterosubstituted acetate taxanes as antitumor agents
JP2021098749A (ja) 新規ヘテロ環状抗エストロゲン剤
BRPI0620126A2 (pt) composto, composição farmacêutica, uso de um composto, método para modular a atividade de um receptor de gabaa, e, método sintético para fabricar um composto
JP2023162228A5 (cg-RX-API-DMAC7.html)
JP2010509216A (ja) ヘテロシクリル置換抗高コレステロール血症化合物
JP2021506898A5 (cg-RX-API-DMAC7.html)
US4833135A (en) Antioestrogenic phenol derivatives
WO2008037626A1 (en) Quinoline derivatives with 5-ht-binding properties
CN101808998A (zh) 在离子性液体基质中制备孟鲁司特酸的方法
CN1070911A (zh) 治疗化合物
JP5168104B2 (ja) 連続鋳造用モールドフラックス
PE20241731A1 (es) Procesos para la preparacion de degradadores selectivos del receptor de estrogeno